>>Signaling Pathways>> Others>>Tafamidis meglumine

Tafamidis meglumine

Catalog No.GC37720

Tafamidis 메글루민(Fx-1006A)은 강력하고 선택적인 트랜스티레틴(TTR) 안정제이며, EC50이 2.7-3.2μM인 돌연변이 동종사량체 V30M-TTR, V122I-TTR 및 야생형 WT-TTR에 필적하는 효능 및 효능을 보여줍니다.

Products are for research use only. Not for human use. We do not sell to patients.

Tafamidis meglumine Chemical Structure

Cas No.: 951395-08-7

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$72.00
재고 있음
5mg
US$65.00
재고 있음
10mg
US$111.00
재고 있음
25mg
US$222.00
재고 있음
50mg
US$380.00
재고 있음
100mg
US$658.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis[1]. EC50: 2.7-3.2 μM (TTR)[1]

Tafamidis binds selectively and with negative cooperativity (Kds ∼2 nM and ∼200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR[1].Tafamidis (0-7.2 μM) dose-dependently inhibits WT-TTR amyloidogenesis after treatment for 72 hours at a pH of 4.4-4.5[1].

[1]. Bulawa CE, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34.

리뷰

Review for Tafamidis meglumine

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tafamidis meglumine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.